Status:
UNKNOWN
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
Lead Sponsor:
Dong-A University
Conditions:
Renal Insufficiency, Chronic
Cardiac Catheterization
Eligibility:
All Genders
20-80 years
Phase:
PHASE4
Brief Summary
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary ...
Eligibility Criteria
Inclusion
- Age\>18 years
- Written informed consent
- Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 \[CKD stage G1-G3\]
- Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients
Exclusion
- Active malignancy
- Class I or equivalent indication for treatment with a SGLT2 inhibitor
- Pregnancy or willing of pregnancy during the follow up period
- Active urogenital infection
- Diabetes mellitus type 1
- History of diabetic ketoacidosis
- Cardiogenic shock
- eGFR \< 29 ml/min/1.73m2
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05225077
Start Date
January 1 2022
End Date
December 31 2023
Last Update
February 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dong A University Hospital
Busan, South Korea, 602-715